Dr. Candelario-Jalil’s research interests have been fostered by nineteen years of work in neuropharmacology, biochemistry and molecular biology. Dr. Candelario-Jalil’s postdoctoral training in Germany and the United States focused upon elucidating the mechanisms underlying the neuroprotective ability of cyclooxygenase-2 (COX-2) inhibitors in experimental animal models of ischemic injury (focal ischemic stroke induced by middle cerebral artery occlusion and global forebrain ischemia). His current research activities are focused on identifying the downstream prostaglandin E2 (PGE2) receptors involved in ischemic brain injury and neuroinflammatory mechanisms responsible for the late opening of the blood-brain barrier following stroke. Other research areas in Dr. Candelario-Jalil’s laboratory include investigation of neurovascular effects of adropin, a recently-identified peptide, in animal models of ischemic stroke. Moreover, another main project involves the study of the role of bromodomain and extraterminal domain (BET) proteins in the neuroinflammatory response to ischemic stroke.